In the first half of the chemical market sales of more than 70 billion, 3 pharmaceutical companies "grab food"

In recent years, the market for public hospital drugs in key cities has grown steadily.
meters intranet data show that in 2019 the market sales have been close to 180 billion yuan, the first half of 2020 affected by the special period, sales of more than 70 billion yuan, but down 17.33 percent year-on-year.
from the first half of 2020 key cities public hospital drug city pattern, the top three are Shanghai, Guangzhou, Beijing, followed by Zhengzhou City, Nanjing City.
, Shanghai and Guangzhou both have sales of more than 8 billion yuan, while Beijing, in third place, and Zhengzhou, fourth, have sales of nearly 2 billion yuan.
from the top 20 manufacturers sales pattern, both multinational pharmaceutical industry and domestic enterprises.
, domestic pharmaceutical companies include Hengrui, Yangzijiang, Qilu, Zhengda Tianqing, Shi Medicine, such as 8 Italian pharmaceutical industry.
And in the top ten, foreign pharmaceutical companies occupy seven seats, namely AstraZeneta, Pfizer, Roche, Bayer, Novarce, Merca East, Sanofi;
is sunny, Bait, stone medicine European meaning closely followed.
From the brand's top 20 competitive landscape, a total of 10 anti-tumor and immunomodulators, including methionate ositini tablets, injection of closta monoantigen, Beda pearl monoantigen injection, etc. ;
, Yangzijiang's neurological drug, Zosin injections, to take the lead with an 87% market share.
the zoxin injection is a variety of pain that requires the use of opioid analgesics.
, sales of Zosin injections in public hospitals in key cities have reached new highs in recent years, and have maintained steady growth after breaking the 1 billion mark.
, only Yangzijiang Pharmaceuticals and Nanjing Yuke Pharmaceuticals have passed the consistent evaluation.
, Nanjing Yuke Pharmaceuticals was approved at the end of 2019, has not yet formed a sales scale.
addition, Enhua Pharmaceuticals and Tianjin Pharmaceutical Research Institute submitted listing applications in categories 3 and 4 respectively in the review and approval, after approval will be treated as passing a consistent evaluation.
Recently, the State Health Insurance Administration issued the "2020 National Health Insurance Drug Catalog Adjustment through the form of examination of the list of declared drugs", Zosin injection is also on the list, analysis pointed out that whether to enter the catalog is mainly to see the pricing strategy of enterprises and price reduction range.
, the growth rate of the new anti-tumor class 1 drug atrotini capsules is staggering, with a market share of 47%.
2018 sales of Antitini capsules in key urban public hospitals have reached nearly 30 million yuan, and in the first half of this year sales have exceeded 300 million yuan, according to the company's internal network.
China Biopharmaceuticals said the launch of hydrochloric acid atrotini capsules has provided an effective new treatment for patients with advanced non-small cell lung cancer in China.
, we need to take full advantage of Theronini's success and focus on the field of cancer.
While Roche's querceto-bead mono-resistance, beval-bead mono-resistance, lytoxi-mono-resistance due to the impact of biosynthic drugs, sales fell sharply, of which, beval-pearl mono-injections fell by more than 10% YoY;
Up to now, only Roche and Fuhong Hanxuan injections have three, Beva beads have Roche, Qilu Pharmaceuticals, Cyntaf, Lytoxi single anti-injections have Roche, Fuhong Hanyu and Cyntharma.
, with the power of domestic pharmaceutical companies, Roche's monopoly market share situation has been broken.